Name | Vidofludimus |
Synonyms | 4SC-101 SC12267) SC12267) Vidofludimus VidofludiMus VidofludiMus(4SC-101 VIDOFLUDIMUS(4SC-101 2-[(3-Fluoro-3'-methoxy-4-biphenylyl)carbamoyl]-1-cyclopentene-1-carboxylic acid 2-[[(3-Fluoro-3'-methoxy[1,1'-biphenyl]-4-yl)amino]carbonyl]-1-cyclopentene-1-carboxylic acid 2-[(3-fluoro-3'-methoxybiphenyl-4-yl)carbamoyl]cyclopent-1-ene-1-carboxylic acid Vidofludimus(4SC-101 |
CAS | 717824-30-1 |
Molecular Formula | C20H18FNO4 |
Molar Mass | 355.36 |
Density | 1.354±0.06 g/cm3(Predicted) |
Boling Point | 567.5±50.0 °C(Predicted) |
Solubility | DMSO: ≥ 46 mg/mL |
pKa | 4?+-.0.20(Predicted) |
Storage Condition | -20℃ |
In vitro study | Vidoflumus concentration-dependently inhibits phytoagglutinin-stimulated PBMC proliferation by inhibiting de Novo Pyrimidine synthesis. Vidoflumus attenuates IL-17 secretion from the band of the colon by Inhibiting STAT3 and NF-κB activation. |
In vivo study | In MRL in rats, Vidofludimus (60 mg/kg, p.o.) effectively reduced the number of macroscopic histopathology and CD3 T cells. In a rat model of kidney transplantation, Vidofludimus (20 mg/kg, p.o.) prolongs survival while improving the histological signature of acute rejection. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.814 ml | 14.07 ml | 28.141 ml |
5 mM | 0.563 ml | 2.814 ml | 5.628 ml |
10 mM | 0.281 ml | 1.407 ml | 2.814 ml |
5 mM | 0.056 ml | 0.281 ml | 0.563 ml |